Evidence map›Paper›PMID 38914124›Full record

Trial reportNature medicine2024

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

Johannes F E Mann, Peter Rossing, George Bakris, Nicolas Belmar, Heidrun Bosch-Traberg, Robert Busch, David M Charytan, Samy Hadjadj, Pieter Gillard, José Luis Górriz and 8 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Observational
  14. Review
  15. Review
  16. Article
  17. Observational
  18. Review
  19. Review
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Johannes F E MannKfH Kidney Centre, München, Germany. johannes.mann@kms.mhn.de.ORCID http://orcid.org/0000-0002-3154-5332
Peter RossingSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID http://orcid.org/0000-0002-1531-4294
George BakrisDepartment of Medicine, AHA Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, IL, USA.
Nicolas BelmarNovo Nordisk A/S, Søborg, Denmark.
Heidrun Bosch-TrabergNovo Nordisk A/S, Søborg, Denmark.
Robert BuschAlbany Medical Center Division of Community Endocrinology, Albany, NY, USA.
David M CharytanNephrology Division, Department of Medicine, New York University Grossman School of Medicine, and NYU Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0002-7695-3583
Samy HadjadjL'Institut du Thorax, CHU Nantes, CNRS, INSERM, Nantes Université, Nantes, France.
Pieter GillardDepartment of Endocrinology, University Hospitals Leuven - KU Leuven, Leuven, Belgium.
José Luis GórrizDepartment of Nephrology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.ORCID http://orcid.org/0000-0002-1134-9051
Thomas IdornNovo Nordisk A/S, Søborg, Denmark.
Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.ORCID http://orcid.org/0000-0002-3262-2168
Kenneth W MahaffeyStanford Center for Clinical Research, Department of Medicine, Stanford School of Medicine, Palo Alto, CA, USA.
Vlado PerkovicFaculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
Søren RasmussenNovo Nordisk A/S, Søborg, Denmark.
Roland E SchmiederDepartment of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University, Erlangen, Germany.ORCID http://orcid.org/0000-0003-2356-5883
Richard E PratleyAdventHealth Translational Research Institute, Orlando, FL, USA.
Katherine R TuttleDivision of Nephrology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2235-0103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People with type 2 diabetes and chronic kidney disease have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) independently reduce CV and kidney events. The effect of combining both is unclear. FLOW trial participants with type 2 diabetes and chronic kidney disease were stratified by baseline SGLT2i use (N = 550) or no use (N = 2,983) and randomized to semaglutide/placebo. The primary outcome was a composite of kidney failure, ≥50% estimated glomerular filtration rate reduction, kidney death or CV death. The risk of the primary outcome was 24% lower in all participants treated with semaglutide versus placebo (95% confidence interval: 34%, 12%). The primary outcome occurred in 41/277 (semaglutide) versus 38/273 (placebo) participants on SGLT2i at baseline (hazard ratio 1.07; 95% confidence interval: 0.69, 1.67; P = 0.755) and in 290/1,490 versus 372/1,493 participants not taking SGLT2i at baseline (hazard ratio 0.73; 0.63, 0.85; P < 0.001; P interaction 0.109). Three confirmatory secondary outcomes were predefined. Treatment differences favoring semaglutide for total estimated glomerular filtration rate slope (ml min

Indexed as

Diabetes Mellitus, Type 2Glomerular Filtration RateGlucagon-Like PeptidesRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAgedCardiovascular DiseasesFemaleHumansHypoglycemic AgentsMaleMiddle AgedSemaglutideTreatment OutcomeGlucagon-Like PeptidesHypoglycemic AgentsSemaglutideSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID38914124
PMCPMC11485243

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.